Prime Medicine expects the following activities and next steps to drive the Prime Editing platform forward: Pipeline Nominate first development candidate for CGD in 1Q 2023. Initiate investigational new drug-enabling studies in CGD in 2023. Expand preclinical proof-of-concept in vivo, including sharing data from in vivo rodent studies and large animal studies in several programs in 2H 2023. Share in vitro preclinical data in additional liver, eye and neuromuscular programs. First IND filing expected as early as 2024 and additional IND filings anticipated in 2025. Platform: Continue to develop and optimize non-viral and viral delivery systems and share additional proof-of-concept data from in vivo rodent and large animal studies in 2H 2023. Further demonstrate superior "off-target" profiles for Prime Editing programs. Expand Prime Editing using proprietary recombinase and/or retrotransposon technologies for new and existing programs.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PRME:
- Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Prime Medicine initiated with an Equal Weight at Morgan Stanley
- Prime Medicine initiated with a Buy at Jefferies
- Prime Medicine initiated with a Neutral at Goldman Sachs
